AURIMUNE Trademark

Trademark Overview

On Thursday, August 30, 2007, a trademark application was filed for AURIMUNE with the United States Patent and Trademark Office. The USPTO has given the AURIMUNE trademark a serial number of 77268112. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 14, 2011. This trademark is owned by CytImmune Sciences, Inc.. The AURIMUNE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, therapeutic nanoparticles for the treatment of cancer
aurimune

General Information

Serial Number77268112
Word MarkAURIMUNE
Filing DateThursday, August 30, 2007
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 14, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 22, 2008

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, therapeutic nanoparticles for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 4, 2007
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCytImmune Sciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20850
Party NameCytImmune Sciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events

Event DateEvent Description
Monday, November 14, 2011ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 14, 2011ABANDONMENT - NO USE STATEMENT FILED
Saturday, March 19, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 18, 2011EXTENSION 5 GRANTED
Friday, March 11, 2011EXTENSION 5 FILED
Friday, March 11, 2011TEAS EXTENSION RECEIVED
Friday, October 8, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 7, 2010EXTENSION 4 GRANTED
Monday, October 4, 2010EXTENSION 4 FILED
Monday, October 4, 2010TEAS EXTENSION RECEIVED
Wednesday, May 26, 2010ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 26, 2010TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 17, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 16, 2010EXTENSION 3 GRANTED
Wednesday, March 10, 2010EXTENSION 3 FILED
Wednesday, March 10, 2010TEAS EXTENSION RECEIVED
Wednesday, October 7, 2009EXTENSION 2 GRANTED
Monday, October 5, 2009EXTENSION 2 FILED
Monday, October 5, 2009TEAS EXTENSION RECEIVED
Tuesday, March 31, 2009EXTENSION 1 GRANTED
Tuesday, March 10, 2009EXTENSION 1 FILED
Tuesday, March 31, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 10, 2009TEAS EXTENSION RECEIVED
Tuesday, October 14, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 22, 2008PUBLISHED FOR OPPOSITION
Wednesday, July 2, 2008NOTICE OF PUBLICATION
Monday, June 16, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, June 13, 2008ASSIGNED TO LIE
Friday, June 13, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 13, 2008ASSIGNED TO EXAMINER
Thursday, June 5, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 5, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 5, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 18, 2007NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 18, 2007NON-FINAL ACTION E-MAILED
Tuesday, December 18, 2007NON-FINAL ACTION WRITTEN
Friday, December 7, 2007ASSIGNED TO EXAMINER
Tuesday, September 4, 2007NEW APPLICATION ENTERED IN TRAM

Related Keywords

aurimune treatment cancer nanoparticles therapeutic preparations namely pharmaceutical